What CAR-T Therapy Actually Costs in China
Not a marketing number. Here is the list price of each approved product, what a realistic all-in treatment budget looks like, how it compares to the US and UK, and exactly what is and isn't included.
The honest, sourced comparison
A 2026 analysis in Asia Times by a George Washington University health-policy professor, discussing patients who had traveled from New Zealand and Australia for CAR-T therapy in Shanghai, put total treatment cost in China at roughly US$150,000 to $230,000, against US$550,000 to $850,000 in the United States for the same class of therapy — a figure consistent with 2025 US wholesale acquisition cost (list price) data for the drug alone, which ranged from about $462,000 (Tecartus) to $593,000 (Kymriah) before any hospitalization or monitoring costs are added.
| Region | Typical all-in range (USD) | Notes |
|---|---|---|
| United States | $550,000 – $850,000 | Includes facility and professional fees on top of 2025 drug list prices of ~$460k–$595k |
| United Kingdom (private pay) | $400,000 – $600,000 | Illustrative; most UK patients access CAR-T through the NHS at no direct cost where commissioned |
| China (via CellBridge China) | $150,000 – $230,000 | Therapy + hospitalization + monitoring; excludes international travel |
Sources: Asia Times (Sept. 2026), Red Book/Micromedex 2025 wholesale acquisition cost data as reported in US pricing-policy analyses, and manufacturer/NMPA pricing disclosures (see product table below). Figures are illustrative ranges for planning purposes, not a quotation for any individual patient.
List price by product (drug only)
These are published list / patient-assistance-programme prices for the therapy itself, converted from CNY at approximately US$1 = ¥7.2 for illustration. They do not include hospitalization, apheresis, lymphodepleting chemotherapy or monitoring — see the all-in estimate above for that.
| Product | Target | List price (approx.) | Patient-assistance price (approx.) |
|---|---|---|---|
| Axi-cel | CD19 | ~$166,700 | ~$111,100 |
| Relma-cel | CD19 | ~$179,200 | ~$130,600 |
| Hengkailai | CD19 | ~$124,900 | ~$76,400 |
| Yuanruida | CD19 | ~$138,750 | ~$83,300 |
| Fukesu | BCMA | ~$162,000 | ~$133,300 |
| Saikaize | BCMA | ~$159,700 | — |
| Kailimei | CLDN18.2 | ~$137,500 | — |
What a complete, honest quotation includes
Press coverage of international CAR-T treatment has rightly criticized quotations that hide the real cost behind an attractive headline number. Every quotation we send is itemized against this checklist:
Typically included
- The CAR-T cell therapy product itself
- Apheresis (cell collection) procedure
- Lymphodepleting chemotherapy
- Inpatient hospitalization through the monitoring period
- Standard management of cytokine release syndrome, if it occurs
- Interpreter services for all clinical appointments
- Scheduled follow-up visits before discharge
Typically excluded — ask for these explicitly
- International flights for patient and companion
- Accommodation beyond the standard included period
- A travel companion's own costs and insurance
- Intensive care, if required beyond the standard monitoring scope
- Treatment of complications outside the agreed scope
- Long-term follow-up imaging or labs after you return home
If a quotation isn't itemized like this, ask why
We will never give you a single bundled number without this breakdown attached. Exclusions should be visible before you commit to travel, not discovered afterward.
How payment works
- Deposit to confirm your treatment slot and begin hospital scheduling, after your eligibility is confirmed.
- Milestone payment on arrival, after confirmatory workup, before apheresis begins.
- Final balance before infusion or per the payment schedule in your signed quotation.
Most international patients pay by bank wire or card; in most cases home-country health insurance does not cover elective overseas cancer treatment, so patients typically self-pay, sometimes supplemented by medical crowdfunding, a charitable grant, or a personal medical loan. We can point you to resources for each but do not provide financial or insurance advice ourselves — see FAQ for more on insurance.